HRP20020205B1 - Dispersion formulations containing lipase inhibitors - Google Patents
Dispersion formulations containing lipase inhibitorsInfo
- Publication number
- HRP20020205B1 HRP20020205B1 HR20020205A HRP20020205A HRP20020205B1 HR P20020205 B1 HRP20020205 B1 HR P20020205B1 HR 20020205 A HR20020205 A HR 20020205A HR P20020205 A HRP20020205 A HR P20020205A HR P20020205 B1 HRP20020205 B1 HR P20020205B1
- Authority
- HR
- Croatia
- Prior art keywords
- formulations containing
- lipase inhibitors
- dispersion formulations
- containing lipase
- polyoxyethylene
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940127470 Lipase Inhibitors Drugs 0.000 title 1
- 239000006185 dispersion Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- -1 polyoxyethylene stearate Polymers 0.000 abstract 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 abstract 2
- 229940086609 Lipase inhibitor Drugs 0.000 abstract 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 abstract 1
- 229930003427 Vitamin E Natural products 0.000 abstract 1
- 150000005215 alkyl ethers Chemical class 0.000 abstract 1
- 239000004359 castor oil Substances 0.000 abstract 1
- 235000019438 castor oil Nutrition 0.000 abstract 1
- 239000002270 dispersing agent Substances 0.000 abstract 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940113116 polyethylene glycol 1000 Drugs 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229940046009 vitamin E Drugs 0.000 abstract 1
- 235000019165 vitamin E Nutrition 0.000 abstract 1
- 239000011709 vitamin E Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99118180 | 1999-09-13 | ||
| PCT/EP2000/008858 WO2001019340A1 (en) | 1999-09-13 | 2000-09-11 | Dispersion formulations containing lipase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20020205A2 HRP20020205A2 (en) | 2004-04-30 |
| HRP20020205B1 true HRP20020205B1 (en) | 2011-06-30 |
Family
ID=8238990
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20020205A HRP20020205B1 (en) | 1999-09-13 | 2002-03-07 | Dispersion formulations containing lipase inhibitors |
Country Status (39)
| Country | Link |
|---|---|
| US (3) | US20030181512A1 (es) |
| EP (1) | EP1216025B1 (es) |
| JP (1) | JP4217016B2 (es) |
| KR (1) | KR100572434B1 (es) |
| CN (1) | CN1197551C (es) |
| AR (1) | AR025587A1 (es) |
| AT (1) | ATE333866T1 (es) |
| AU (1) | AU769415B2 (es) |
| BR (2) | BR0013939A (es) |
| CA (1) | CA2383916C (es) |
| CO (1) | CO5180587A1 (es) |
| CY (1) | CY1106180T1 (es) |
| CZ (1) | CZ301901B6 (es) |
| DE (1) | DE60029602T2 (es) |
| DK (1) | DK1216025T3 (es) |
| EG (1) | EG24117A (es) |
| ES (1) | ES2267563T3 (es) |
| HK (1) | HK1049966A1 (es) |
| HR (1) | HRP20020205B1 (es) |
| HU (1) | HU228858B1 (es) |
| IL (1) | IL148494A0 (es) |
| JO (1) | JO2386B1 (es) |
| MA (1) | MA26818A1 (es) |
| ME (1) | ME00674B (es) |
| MX (1) | MXPA02002034A (es) |
| MY (1) | MY130200A (es) |
| NO (1) | NO331906B1 (es) |
| NZ (1) | NZ517545A (es) |
| PE (1) | PE20010595A1 (es) |
| PL (1) | PL199870B1 (es) |
| PT (1) | PT1216025E (es) |
| RS (1) | RS50422B (es) |
| RU (1) | RU2239428C2 (es) |
| SI (1) | SI1216025T1 (es) |
| TR (1) | TR200200606T2 (es) |
| TW (1) | TWI243060B (es) |
| UY (1) | UY26338A1 (es) |
| WO (1) | WO2001019340A1 (es) |
| ZA (1) | ZA200201518B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1307264T1 (en) * | 2000-07-28 | 2005-02-28 | F. Hoffmann-La Roche Ag | New pharmaceutical composition |
| US20030027786A1 (en) * | 2001-06-06 | 2003-02-06 | Karsten Maeder | Lipase inhibiting composition |
| US6730319B2 (en) | 2001-06-06 | 2004-05-04 | Hoffmann-La Roche Inc. | Pharmaceutical compositions having depressed melting points |
| US8372430B2 (en) | 2002-12-17 | 2013-02-12 | The Procter & Gamble Company | Compositions, methods, and kits useful for the alleviation of gastrointestinal effects |
| FI20045076A (fi) * | 2004-03-15 | 2005-09-16 | Bioferme Oy | Funktionaalinen elintarvike |
| US8241664B2 (en) * | 2005-04-15 | 2012-08-14 | Clarus Therapeutics, Inc | Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same |
| KR100910000B1 (ko) * | 2005-05-13 | 2009-07-29 | 씨제이제일제당 (주) | 리파아제 저해제 함유 약학 조성물 |
| ES2434072T3 (es) * | 2005-06-09 | 2013-12-13 | Norgine Bv | Preparación sólida de 2-hexadeciloxi-6-metil-4H-3,1-benzoxacin-4-ona |
| KR100669497B1 (ko) * | 2005-08-17 | 2007-01-16 | 보람제약주식회사 | 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법 |
| WO2007033522A1 (fr) * | 2005-09-21 | 2007-03-29 | Shenzhen Tys R & D Co., Ltd. | Formulation de gélule contenant de la moxifloxacine et son procédé de préparation |
| KR101252635B1 (ko) | 2006-04-20 | 2013-04-10 | (주)아모레퍼시픽 | 리파아제 저해제 및 친유성 오일흡수제를 포함하는 약학조성물 및 이로부터 제조된 경구 투여용 제제 |
| TR200607613A2 (tr) * | 2006-12-29 | 2008-07-21 | NOBEL İLAÇ SAN.ve TiC.A.Ş. | Lipaz inhibitörü içeren farmasötik formülasyonlar |
| EP1970051A1 (en) * | 2007-03-14 | 2008-09-17 | Merz Pharma GmbH & Co.KGaA | Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases |
| KR101439470B1 (ko) * | 2007-05-22 | 2014-09-16 | 한미사이언스 주식회사 | 오를리스타트 및 대변 연화제를 포함하는 비만의 예방 또는치료용 조성물 |
| ATE477820T1 (de) * | 2007-09-12 | 2010-09-15 | Mader S R L | Pharmazeutische zusammensetzungen zur oralen verabreichung bei der behandlung von adipositas- patienten |
| EP2044930A1 (en) * | 2007-10-01 | 2009-04-08 | Nestec S.A. | Composition for controlling lipase catalyzed reactions |
| PL216542B1 (pl) | 2008-03-20 | 2014-04-30 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku |
| WO2010042499A1 (en) * | 2008-10-06 | 2010-04-15 | Banner Pharmacaps, Inc. | Stable solutions of orlistat for pharmaceutical dosage forms |
| KR20100075260A (ko) * | 2008-12-24 | 2010-07-02 | 주식회사종근당 | 리파아제 저해제의 부작용 개선을 위한 신규한 약제학적 조성물 |
| BRPI0901602B8 (pt) | 2009-04-03 | 2021-05-25 | Ems S/A | formulação farmacêuticas |
| ITRM20120331A1 (it) | 2012-07-12 | 2014-01-13 | Guidotti & C Spa Labor | Composizioni pediatriche orali liquide contenenti nepadutant. |
| BR112017021995A2 (pt) * | 2015-04-14 | 2018-07-10 | Zim Laboratories Ltd | formulação farmacêutica compreendendo drogas de baixa fusão e altamente lipofílicas e método de melhora da dissolução |
| CN106310287B (zh) * | 2015-06-25 | 2019-03-19 | 山东省药学科学院 | 新利司他药用组合物及其制备方法 |
| MY196635A (en) * | 2018-06-22 | 2023-04-25 | Sime Darby Plantation Intellectual Property Sdn Bhd | Method For Reducing Formation of Free Fatty Acids in Plants |
| CN115105476B (zh) * | 2021-03-23 | 2023-11-14 | 山东新时代药业有限公司 | 一种奥利司他冻干口服制剂及其制备工艺 |
| CN114983938A (zh) * | 2022-05-19 | 2022-09-02 | 广东嘉博制药有限公司 | 一种奥利司他口服复合乳液及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998034607A1 (en) * | 1997-02-05 | 1998-08-13 | F. Hoffmann-La Roche Ag | Tetrahydrolipstatin containing compositions |
| WO1998034630A1 (en) * | 1997-02-05 | 1998-08-13 | F.Hoffmann-La Roche Ag | Use of gastrointestinal lipase inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247547A (en) | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| EP0281200B1 (en) * | 1987-03-02 | 1994-01-19 | Yamanouchi Europe B.V. | Pharmaceutical composition, pharmaceutical granulate and process for their preparation |
| TW381025B (en) | 1993-08-05 | 2000-02-01 | Hoffmann La Roche | Pharmaceutical composition containing a glucosidase inhibitor and a lipase inhibitor |
| IT1282673B1 (it) | 1996-02-23 | 1998-03-31 | Ist Naz Stud Cura Dei Tumori | Derivati della camptotecina e loro uso come agenti antitumorali |
| US5891469A (en) * | 1997-04-02 | 1999-04-06 | Pharmos Corporation | Solid Coprecipitates for enhanced bioavailability of lipophilic substances |
| AU730216B2 (en) | 1996-09-01 | 2001-03-01 | Pharmos Corporation | Solid coprecipitates for enhanced bioavailability of lipophilic substances |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| TR200100472T2 (tr) | 1998-08-14 | 2001-07-23 | F.Hoffmann-La Roche Ag | Lipaz inhibitörleri ile sitozan içeren farmasötik bileşimler |
| WO2000009122A1 (en) | 1998-08-14 | 2000-02-24 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions containing lipase inhibitors |
| US6368622B2 (en) * | 1999-01-29 | 2002-04-09 | Abbott Laboratories | Process for preparing solid formulations of lipid regulating agents with enhanced dissolution and absorption |
-
2000
- 2000-09-07 AR ARP000104679A patent/AR025587A1/es not_active Application Discontinuation
- 2000-09-11 AU AU72863/00A patent/AU769415B2/en not_active Expired
- 2000-09-11 CZ CZ20021276A patent/CZ301901B6/cs not_active IP Right Cessation
- 2000-09-11 SI SI200030888T patent/SI1216025T1/sl unknown
- 2000-09-11 BR BR0013939-4A patent/BR0013939A/pt not_active IP Right Cessation
- 2000-09-11 WO PCT/EP2000/008858 patent/WO2001019340A1/en active IP Right Grant
- 2000-09-11 ES ES00960643T patent/ES2267563T3/es not_active Expired - Lifetime
- 2000-09-11 CN CNB008126801A patent/CN1197551C/zh not_active Expired - Lifetime
- 2000-09-11 DK DK00960643T patent/DK1216025T3/da active
- 2000-09-11 EP EP00960643A patent/EP1216025B1/en not_active Expired - Lifetime
- 2000-09-11 BR BRPI0013939-4A patent/BRPI0013939B1/pt unknown
- 2000-09-11 NZ NZ517545A patent/NZ517545A/en not_active IP Right Cessation
- 2000-09-11 TR TR2002/00606T patent/TR200200606T2/xx unknown
- 2000-09-11 IL IL14849400A patent/IL148494A0/xx active IP Right Grant
- 2000-09-11 PL PL356174A patent/PL199870B1/pl unknown
- 2000-09-11 PT PT00960643T patent/PT1216025E/pt unknown
- 2000-09-11 ME MEP-2008-908A patent/ME00674B/me unknown
- 2000-09-11 MX MXPA02002034A patent/MXPA02002034A/es active IP Right Grant
- 2000-09-11 RU RU2002107428/15A patent/RU2239428C2/ru active
- 2000-09-11 CA CA002383916A patent/CA2383916C/en not_active Expired - Lifetime
- 2000-09-11 DE DE60029602T patent/DE60029602T2/de not_active Expired - Lifetime
- 2000-09-11 JP JP2001522975A patent/JP4217016B2/ja not_active Expired - Lifetime
- 2000-09-11 KR KR1020027003269A patent/KR100572434B1/ko active IP Right Grant
- 2000-09-11 HU HU0202737A patent/HU228858B1/hu unknown
- 2000-09-11 RS YUP-172/02A patent/RS50422B/sr unknown
- 2000-09-11 AT AT00960643T patent/ATE333866T1/de active
- 2000-09-12 JO JO2000157A patent/JO2386B1/en active
- 2000-09-12 EG EG20001159A patent/EG24117A/xx active
- 2000-09-12 UY UY26338A patent/UY26338A1/es not_active Application Discontinuation
- 2000-09-12 CO CO00068859A patent/CO5180587A1/es active IP Right Grant
- 2000-09-13 MY MYPI20004253A patent/MY130200A/en unknown
- 2000-09-13 PE PE2000000949A patent/PE20010595A1/es not_active IP Right Cessation
- 2000-10-19 TW TW089121968A patent/TWI243060B/zh not_active IP Right Cessation
-
2002
- 2002-02-22 ZA ZA200201518A patent/ZA200201518B/xx unknown
- 2002-03-07 HR HR20020205A patent/HRP20020205B1/xx not_active IP Right Cessation
- 2002-03-11 MA MA26545A patent/MA26818A1/fr unknown
- 2002-03-12 NO NO20021204A patent/NO331906B1/no not_active IP Right Cessation
-
2003
- 2003-03-25 HK HK03102148A patent/HK1049966A1/xx not_active IP Right Cessation
- 2003-04-21 US US10/419,346 patent/US20030181512A1/en not_active Abandoned
-
2004
- 2004-03-05 US US10/794,123 patent/US8012494B2/en not_active Expired - Lifetime
-
2006
- 2006-09-29 CY CY20061101416T patent/CY1106180T1/el unknown
-
2011
- 2011-07-19 US US13/185,558 patent/US20110275706A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998034607A1 (en) * | 1997-02-05 | 1998-08-13 | F. Hoffmann-La Roche Ag | Tetrahydrolipstatin containing compositions |
| WO1998034630A1 (en) * | 1997-02-05 | 1998-08-13 | F.Hoffmann-La Roche Ag | Use of gastrointestinal lipase inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20020205B1 (en) | Dispersion formulations containing lipase inhibitors | |
| ES2169121T3 (es) | Composiciones farmaceuticas que contienen agentes inhibidores de proteasa de hiv. | |
| DE69711637T2 (de) | Aerosolformulierungen | |
| HK1036931A1 (en) | Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients. | |
| PT762896E (pt) | Composicoes de tocoferol para administracao de agentes biologicamente activos | |
| CY1108532T1 (el) | Ενωσεις και συνθεσεις για την παροχη δραστικων παραγοντων | |
| ATE257695T1 (de) | Fluorkohlenwasserstoff-treibgas enthaltende medizinische aerosole | |
| EA200301139A1 (ru) | Самоэмульгирующиеся препараты ингибиторов белка-переносчика эфиров холестерина | |
| MY118151A (en) | Pharmaceutical formulations containing voriconazole. | |
| AU2002316811A1 (en) | Stable formulation of modified glp-1 | |
| RS50504B (sr) | Tečne formulacije | |
| DK1073467T3 (da) | Formuleringer med co-oplösningsmiddel omfattende en forbindelse af vitamin D | |
| ES2108422T3 (es) | Combinaciones sinergicas de productos antisolares y composiciones cosmeticas y dermatologicas que las contienen. | |
| PT896534E (pt) | Formulacoes para injeccao de avermectinas e milbemicinas a base de oleo de ricino | |
| AU3868997A (en) | Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol | |
| PL328916A1 (en) | Compositions containing inhibitors of hiv protease, such as vx 478 and water-soluble vitamin e compound such as vitamin e-tpgs | |
| AU3777197A (en) | Cyclosporin formulation | |
| MXPA03010672A (es) | Composicion para el tratamiento regenerativo de enfermedades del cartilago. | |
| ES2191426T3 (es) | Composiciones estables que comprenden levosimendano y acido alginico. | |
| MX9602984A (es) | Composiciones farmaceuticas que contienen inhibidores de proteasa de vih. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| B1PR | Patent granted | ||
| PPPP | Transfer of rights |
Owner name: CHEPLAPHARM ARZNEIMITTEL GMBH, DE |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20190905 Year of fee payment: 20 |
|
| PB20 | Patent expired after termination of 20 years |
Effective date: 20200911 |